Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04708782 · ClinicalTrials.gov registry record · Phase 3
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
A Phase 3 study, sponsored by United Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 598
- Enrollment target
NCT04708782 is a Phase 3 study that has completed, run by United Therapeutics. The registered enrollment target is 598 participants.
The verdict
NCT04708782, a Phase 3 study, has completed, sponsored by United Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 598 participants
- Enrollment target
Study Summary
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
Interventions
- DRUG Placebo
- DRUG Inhaled Treprostinil
- DEVICE Treprostinil Ultrasonic Nebulizer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 598 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2026-02-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04708782
The ClinicalTrials.gov registry entry for NCT04708782 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 598 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04708782 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04708782 about?
NCT04708782 is a clinical study titled "Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis". Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
What is the current status of trial NCT04708782?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 598 participants. The study started on 2021-06-01. Estimated completion is 2026-02-02.
What interventions are being tested in trial NCT04708782?
The interventions under investigation include: Placebo (DRUG), Inhaled Treprostinil (DRUG), Treprostinil Ultrasonic Nebulizer (DEVICE).
Who is sponsoring clinical trial NCT04708782?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.